IBDEI347 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,49749,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,49749,1,2,0)
 ;;=2^96171
 ;;^UTILITY(U,$J,358.3,49749,1,3,0)
 ;;=3^Hlth Bhv Intv,Fam w/o Pt,Ea Addl 15 min
 ;;^UTILITY(U,$J,358.3,49750,0)
 ;;=96158^^192^2481^7^^^^1
 ;;^UTILITY(U,$J,358.3,49750,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,49750,1,2,0)
 ;;=2^96158
 ;;^UTILITY(U,$J,358.3,49750,1,3,0)
 ;;=3^Hlth Bhv Intv,Ind,1st 30 min
 ;;^UTILITY(U,$J,358.3,49751,0)
 ;;=96159^^192^2481^8^^^^1
 ;;^UTILITY(U,$J,358.3,49751,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,49751,1,2,0)
 ;;=2^96159
 ;;^UTILITY(U,$J,358.3,49751,1,3,0)
 ;;=3^Hlth Bhv Intv,Ind,Ea Addl 15 min
 ;;^UTILITY(U,$J,358.3,49752,0)
 ;;=B18.2^^193^2482^38
 ;;^UTILITY(U,$J,358.3,49752,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49752,1,3,0)
 ;;=3^Hepatitis C,Chr
 ;;^UTILITY(U,$J,358.3,49752,1,4,0)
 ;;=4^B18.2
 ;;^UTILITY(U,$J,358.3,49752,2)
 ;;=^5000548
 ;;^UTILITY(U,$J,358.3,49753,0)
 ;;=E11.9^^193^2482^23
 ;;^UTILITY(U,$J,358.3,49753,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49753,1,3,0)
 ;;=3^Diabetes Type 2
 ;;^UTILITY(U,$J,358.3,49753,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,49753,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,49754,0)
 ;;=E11.40^^193^2482^21
 ;;^UTILITY(U,$J,358.3,49754,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49754,1,3,0)
 ;;=3^DM Type 2 w/ Neuropathy
 ;;^UTILITY(U,$J,358.3,49754,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,49754,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,49755,0)
 ;;=E78.2^^193^2482^39
 ;;^UTILITY(U,$J,358.3,49755,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49755,1,3,0)
 ;;=3^Hyperlipidemia,Mixed
 ;;^UTILITY(U,$J,358.3,49755,1,4,0)
 ;;=4^E78.2
 ;;^UTILITY(U,$J,358.3,49755,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,49756,0)
 ;;=E78.5^^193^2482^40
 ;;^UTILITY(U,$J,358.3,49756,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49756,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,49756,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,49756,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,49757,0)
 ;;=E66.3^^193^2482^57
 ;;^UTILITY(U,$J,358.3,49757,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49757,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,49757,1,4,0)
 ;;=4^E66.3
 ;;^UTILITY(U,$J,358.3,49757,2)
 ;;=^5002830
 ;;^UTILITY(U,$J,358.3,49758,0)
 ;;=F17.200^^193^2482^50
 ;;^UTILITY(U,$J,358.3,49758,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49758,1,3,0)
 ;;=3^Nicotine Dependence,Unspec
 ;;^UTILITY(U,$J,358.3,49758,1,4,0)
 ;;=4^F17.200
 ;;^UTILITY(U,$J,358.3,49758,2)
 ;;=^5003360
 ;;^UTILITY(U,$J,358.3,49759,0)
 ;;=G43.909^^193^2482^48
 ;;^UTILITY(U,$J,358.3,49759,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49759,1,3,0)
 ;;=3^Migraine,Unspec
 ;;^UTILITY(U,$J,358.3,49759,1,4,0)
 ;;=4^G43.909
 ;;^UTILITY(U,$J,358.3,49759,2)
 ;;=^5003909
 ;;^UTILITY(U,$J,358.3,49760,0)
 ;;=H91.93^^193^2482^34
 ;;^UTILITY(U,$J,358.3,49760,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49760,1,3,0)
 ;;=3^Hearing Loss,Bilateral
 ;;^UTILITY(U,$J,358.3,49760,1,4,0)
 ;;=4^H91.93
 ;;^UTILITY(U,$J,358.3,49760,2)
 ;;=^5006944
 ;;^UTILITY(U,$J,358.3,49761,0)
 ;;=I10.^^193^2482^41
 ;;^UTILITY(U,$J,358.3,49761,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49761,1,3,0)
 ;;=3^Hypertension
 ;;^UTILITY(U,$J,358.3,49761,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,49761,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,49762,0)
 ;;=I50.9^^193^2482^17
 ;;^UTILITY(U,$J,358.3,49762,1,0)
 ;;=^358.31IA^4^2
